2025年5月28日 周三
Home > Archive>Volume 29, Issue 1, 2021 >87-92
PDF HTML XML Export Cite reminder
Research progress on the relationship between metabolites of intestinal microflora and myocardial fibrosis
Author:
Affiliation:

1.Shanxi Medical University, Taiyuan, Shanxi 030001, China;2.Department of Cardiology, the Second Hospital of Shanxi Medical University, Taiyuan, Shanxi 030013, China)

Clc Number:

R5

  • Article
    • | |
  • Metrics
    • |
  • Reference [43]
    • | | | |
  • Comments
    Abstract:

    Aim Myocardial fibrosis(MF)is characterized by extracellular matrix accumulation, fibroblast activation, and transformation into myofibroblast, which is one of the features of cardiac remodeling after cardiac injury. MF includes two basic types:reactive fibrosis and repair fibrosis. Two kinds of fibrosis often coexist in the process of ventricular remodeling. MF can lead to congestive heart failure, malignant arrhythmia and sudden death, and become an important cause of sustainable development and irreversible ventricular remodeling. Some studies have shown that metabolites of intestinal flora, including trimethylamine oxide, short chain fatty acids, indole oxyl sulfate and p cresol sulfate, are involved in the process of myocardial fibrosis and play an important role in the treatment of heart failure. It is expected to become a new target for the treatment of heart failure. In this paper, the mechanism of intestinal flora metabolites in myocardial fibrosis is described, and the research progress of improving myocardial fibrosis by intervention of intestinal flora is also introduced.

    Reference
    [1] Cerf BN, Gaboriau RV.The immune system and the gut microbiota:friends or foes?.Nat Rev Immunol, 0,0(10):735-744.
    [2] Tremaroli V, Bckhed F.Functional interactions between the gut microbiota and host metabolism.Nature, 2,9(7415):242-249.
    [3] Mamic P, Heidenreich PA, Hedlin H, et al.Hospitalized patients with heart failure and common bacterial infections:a nationwide analysis of concomitant clostridium difficile infection rates and in-hospital mortality.J Card Fail, 6,2(11):891-900.
    [4] Cui X, Ye L, Li J, et al.Metagenomic and metabolomic analyses unveil dysbiosis of gut microbiota in chronic heart failure patients.Sci Rep, 8,8(1):635-650.
    [5] Sekirov I, Russell SL, Antunes LC, et al.Gut microbiota inhealth and disease .Physiol Rev, 0,0(3):859-904.
    [6] Nallu A, Sharma S, Ramezani A, et al.Gut microbiome inchronic kidney disease:challenges and opportunities.Transl Res, 7,9:24-37.
    [7] Tang WH, Li DY, Hazen SL.Dietary metabolism, the gut microbiome, and heart failure.Nat Rev Cardiol, 9,6(3):137-154.
    [8] Tang WH, Wang Z, Fan Y, et al.Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure:refining the gut hypothesis.J Am Coll Cardiol, 4,4(18):1908-1914.
    [9] Lever M, George PM, Slow S, et al.Betaine and trimethylamine-N-oxide as predictors of cardiovascular outcomes show different patterns in diabetes mellitus:an observational study.PloS One, 4,9(12):e114969.
    [10] Yang WL, Zhang SN, Zhu JB, et al.Gut microbe-derived metabolite trimethylamine N-oxide accelerates fibroblast-myofibroblast differentiation and induces cardiac fibrosis.J Mol Cell Cardiol, 9,4:119-130.
    [11] Li ZH, Wu ZY, Yan JY, et al.Gut microbe-derived metabolite trimethylamine N-oxide induces cardiac hypertrophy and fibrosis.Lab Invest, 9,9(3):346-357.
    [12] Organ CL, Otsuka H, Bhushan S, et al.Choline diet and its gut microbe-derived metabolite, trimethylamine N-oxide, exacerbate pressure overload-induced heart failure.Circ Heart Fail, 6,9(1):e002314.
    [13] Tomasz H, Adrian D, Marta G, et al.Chronic, low-dose TMAO treatment reduces diastolic dysfunction and heart fibrosis in hypertensive rats.Am J Physiol Heart Circ Physiol, 8,5(6):H1805-H1820.
    [14] Patra S, Anders C, Schummel PH, et al.Antagonistic effects of natural osmolyte mixtures and hydrostatic pressure on the conformational dynamics of a DNA hairpin probed at the single-molecule level.Phys Chem Chem Phys, 8,0(19):13159-13170.
    [15] Yancey PH, Siebenaller JF.Co-evolution of proteins and solutions:protein adaptation versus cytoprotective micromolecules and their roles in marine organisms.J Exp Biol, 5,8(Pt 12):1880-1896.
    [16] Yancey PH, SpeersRB, Atchinson S, et al.Osmolyte adjustments as a pressure adaptation in deep-sea chondrichthyan fishes:an intraspecific test in arctic skates (amblyraja hyperborea) along a depth gradient.Physiol Biochem Zool, 8,1(2):788-796.
    [17] Yin QJ, Zhang WJ, Qi XQ, et al.High hydrostatic pressure inducible trimethylamine N -oxide reductase improves the pressure tolerance of piezosensitive bacteria vibrio fluvialis .Front Microbiol, 7,8:2646.
    [18] Wang WJ, Cheng MH, Sun MF, et al.Indoxyl sulfate induces renin release and apoptosis of kidney mesangial cells.J Toxicol Sci, 4,9(4):637-643.
    [19] Ito S, Yoshida M.Protein-bound uremic toxins:new culprits of cardiovascular events in chronic kidney disease patients.Toxins (Basel), 4,6(2):665-678.
    [20] Lin CJ, Chuang CK, Jayakumar T, et al.Serum p-cresyl sulfate predicts cardiovascular disease and mortality in elderly hemodialysis patients.Arch Med Sci, 3,9(4):662-668.
    [21] Yisireyili M, Shimizu H, Saito S, et al.Indoxyl sulfate promotes cardiac fibrosis with enhanced oxidative stress in hypertensive rats.Life Sci, 3,2(24-26):1180-1185.
    [22] Aoki K, Teshima Y, Kondo H, et al.Role of indoxyl sulfate as a predisposing factor for atrial fibrillation in renal dysfunction.J Am Heart Assoc, 5,4(10):e002023.
    [23] Lekawanvijit S, Kompa AR, Manabe M, et al.Chronic kidney disease-induced cardiac fibrosis is ameliorated by reducing circulating levels of a non-dialysable uremic toxin, indoxyl sulfate.PloS One, 2,7(7):e41281.
    [24] Savira F, Cao L, Wang L, et al.Apoptosis signal-regulating kinase 1 inhibition attenuates cardiac hypertrophy and cardiorenal fibrosis induced by uremic toxins:Implications for cardiorenal syndrome.PloS One, 7,2(11):e0187459.
    [25] Rana I, Kompa AR, Skommer J, et al.Contribution of microRNA to pathological fibrosis in cardio-renal syndrome:impact of uremic toxins.Physiol Rep, 5,3(4):e12371.
    [26] Lekawanvijit S, Adrahtas A, Kelly DJ, et al.Does indoxyl sulfate, a uraemic toxin, have direct effects on cardiacfibroblasts and myocytes?.Eur Heart J, 0,1(14):1771-1779.
    [27] Yang K, Xu X, Nie L, et al.Indoxyl sulfate induces oxidative stress and hypertrophy in cardiomyocytes by inhibiting the AMPK/UCP2 signaling pathway.Toxicology Letters, 5,4(2):110-119.
    [28] Koh A, De VF, Kovatcheva DP, et al.From dietary fiber to host physiology:short-chain fatty acids as key bacterial metabolites.Cell, 6,5(6):1332-1345.
    [29] LeBlanc JG, Chain F, Martín R, et al.Beneficial effects on host energy metabolism of short-chain fatty acids and vitamins produced by commensal and probiotic bacteria.Microb Cell Fact, 7,6(1):79.
    [30] De VF, Kovatcheva DP, Goncalves D, et al.Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits.Cell, 4,6(1-2):84-96.
    [31] Donohoe DR, Garge N, Zhang X, et al.The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon.Cell Metabolism, 1,3(5):517-526.
    [32] Brown AJ, Goldsworthy SM, Barnes AA, et al.The orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids.J Biol Chem, 3,8(13):11312-11319.
    [33] Whelton SP, Hyre AD, Pedersen B, et al.Effect of dietary fiber intake on blood pressure:a meta-analysis of randomized, controlled clinical trials.J Hypertens, 5,3(3):475-481.
    [34] Khalesi S, Sun J, Buys N, et al.Effect of probiotics on blood pressure:a systematic review andmeta-analysis of randomized, controlled trials.Hypertension, 4,4(4):897-903.
    [35] Marques FZ, Nelson E, Chu PY, et al.High-fiber diet and acetate supplementation change the gut microbiota and prevent the development of hypertension and heart failure in hypertensive mice.Circulation, 7,5(10):964-977.
    [36] Hiroshi A, Hyemoon C, Shin I, et al.AST-120,an Adsorbent of irenic toxins, improve the path physiology of heart failure in conscious dogs.Cardiovasc Drugs Ther, 9,3(3):277-286.
    [37] Roberts AB, Gu XD, Buffa JA, et al.Development of a gut microbe-targeted nonlethal therapeutic to inhibit thrombosis potential.Nat Med, 8,4(9):1407-1417.
    [38] Wang ZN, Roberts AB, BUFFA JA, et al.Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis.Cell, 5,3(7):1585-1595.
    [39] McGuire Shelley.Scientific Report of the 2015 Dietary Guidelines Advisory Committee.Washington, DC:US Departments of Agriculture and Health and Human Services, 2015 .Adv Nutr (Bethesda), 6,7(1):202-204.
    [40] De FF, Pellegrini N, Vannini L, et al.High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome.Gut, 6,5(11):1812-1821.
    [41] Qiu L, Tao XY, Xiong H, et al.Lactobacillus plantarum ZDY04 exhibits a strain-specific property of lowering TMAO via the modulation of gut microbiota in mice.Food Funct, 8,9(8):4299-4309.
    [42] Cani PD, Possemiers S, Van WT, et al.Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability.Gut, 9,8(8):1091-1103.
    [43] Cani PD, Neyrinck AM, Fava F, et al.Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia.Diabetologia, 7,0(11):2374-2383.
    Related
    Cited by
    Comments
    Comments
    分享到微博
    Submit
Get Citation

HAN Bingqing, BAI Chunlin. Research progress on the relationship between metabolites of intestinal microflora and myocardial fibrosis[J]. Editorial Office of Chinese Journal of Arteriosclerosis,2021,29(1):87-92.

Copy
Share
Article Metrics
  • Abstract:569
  • PDF: 953
  • HTML: 0
  • Cited by: 0
History
  • Received:December 10,2019
  • Revised:March 26,2020
  • Online: January 22,2021
Article QR Code

You are the 50097 visitor

Post Code：421001 Fax：0734-8160523

Phone：0734-8160765 E-mail：dmzzbjb@163.net

Editorial Office of Chinese Journal of Arteriosclerosis ® 2025